The group notes that the FDA suspended in-person requirements for many other drugs during the pandemic, including opioids, but kept them in place for mifepristone.
The group notes that the FDA suspended in-person requirements for many other drugs during the pandemic, including opioids, but kept them in place for mifepristone.
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться